Amgen Inc.

3 days ago · zacks.com

The latest trading day saw Amgen (AMGN) settling at $460.73, representing a +1.97% change from its previous close.

3 days ago · zacks.com

Beyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

4 days ago · 247wallst.com

Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned that spending will jump.

4 days ago · prnewswire.com

THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial markets.

4 days ago · zacks.com

Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.

5 days ago · prnewswire.com

/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the fourth quarter of 2026. The

5 days ago · fool.com

Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.

5 days ago · zacks.com

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 days ago · fool.com

Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net margin of 33.1%.

6 days ago · seekingalpha.com

On November 3, Amgen Inc. will report its results for Q3. As a reminder, its Q2 non-GAAP EPS rose 25.8% quarter-on-quarter to $6.29, primarily due to the strong performance of biosimilars, Blincyto, and Repatha. On October 24, Amgen released promising results from the DeLLphi-305 study evaluating Imdelltra+Imfinzi in the treatment of extensive-stage small-cell lung cancer.